



## **ISO 11607 - 1 & 2 Packaging for Terminally Sterilized Medical Devices**

**Jan Gates:** Adept Packaging LLC

10X Conference, May 2019



# Jan Gates

Principal Packaging Engineer, Adept Packaging  
VP Client Solutions, West Coast


- Over 35+ years in medical devices, foods, pharmaceutical and detergent industries
- Packaging engineering experience in design, material and distribution testing, material and equipment validations, PMA submissions, REACH/RoHS, EU Packaging Waste Directives, and sustainability
- SoCal Institute of Packaging Professionals Chapter, Co-President
- IoPP Medical Device Packaging Technical Committee, member
- ASTM F02, Flexible Barrier Packaging member
- ASTM D10, Rigid/Environmental Packaging and Testing committee member
- D10.96 ISO TC122 SC3 TAG Liaison Chair
- ISO TC122 WG5 Covenor – Vocabulary
- ISO TC122 WG13 (Labels) & WG16 (Controlled Temperature Packaging) SME




# Some of My Old Work



# Some of My Current Work



# Package Engineering Summary



## Standard Titles



**ISO 11607-1:** *Packaging for terminally sterilized medical devices – part one*

- ✓ Design and development

**ISO 11607-2:** *Packaging for terminally sterilized medical devices – part two*

- ✓ Equipment and process validations

Current revisions: 2019 February

# Background



## EN ISO 11607-1 & -2

- ✓ Replaced EN 868-1
- ✓ FDA harmonized with standard in 2006

## AAMI TIR 22

Issued April 2007

- ✓ US Guidance Document to EN ISO 11607-1 & -2
- ✓ More DDD guidance included for FDA

## ISO/TS 16775

Issued, May 2014, replaced TIR 22

- ✓ ISO Guidance on the application of ISO 11607-1 and ISO 11607-2
- ✓ Minor revisions to the ISO 11607-1/-2 standard

## Revised ISO

11607-1/-2 published, February 2019

- ✓ Revisions with human factors/use added and critical process parameter definition changes





## ISO 11607 -1/-2 Standards

**Standardized packaging for terminally sterilized medical devices**

*(placed packaging on the same importance level as the product; a medical device does not remain sterile without acceptable packaging; qualify/validate the packaging system)*





## New Terminology was Introduced



- Terminal Sterilization
- Sterile Barrier System (SBS)
- Preformed Sterile Barrier System
- Protective Packaging
- Packaging System
- Seal Integrity
- Aseptic Presentation
- Stability Testing
- Performance Testing

## Terminal Sterilization & Packaging

### Sterilization validation

- ✓ Follow sterilization standards with worst-case situations for packaging
- ✓ Understand Biological Indicators (BI) and placements

*Short hand* → Sterilization kills the microbes inside the packaging; packaging must not have holes until opened for use

*<keep holes out of the SBS during packaging, storage, shipment, and handling>*

### Common Types of Sterilization



*Gamma*



*Ethylene oxide*



*E-beam*



*Hydrogen Peroxide*



**Shall Statements : Statements required for compliance**



# Sampling of Shall Statements

**Over 115 “SHALL”  
statements in the ISO  
11607 documents,  
this includes:**




- ✓ Shall use sampling plans based on statistically valid rationale (-1, Clause 4.3)
- ✓ Shall establish and record a rationale for appropriate tests and acceptance criteria (-1/-2, Clause 4.4)
- ✓ Shall allow aseptic product presentation from the sterile barrier system. Note: Completing a usability evaluation can demonstrate this. (-1, Clause 6.1.2)
- ✓ Shall have procedures for packaging system design and development (-1, Clause 6.2.1)
- ✓ Shall have test methods validated and documented by the laboratory performing the test (-1, Clause 4.4.3)
- ✓ Shall have EQ: IQ/OQ equipment (-2, Clauses 5.2 and 5.3)
- ✓ Shall have written preventative maintenance and cleaning schedules (-2, Clause 5.2.6)
- ✓ Shall have a minimum of three production runs for a PQ (-2, 5.4.4)
- ✓ Shall test product for acceptability after transit testing with or without the sterile barrier integrity testing (-1, Clause 8.2.1 Note 2)
- ✓ Shall start real time stability testing within three months of accelerated testing before commercialization (-1, Clause 8.3.4)
- ✓ Stability and performance testing are separate entities (-1, Clause 8.1 Note 2)



# Statistical Justification


A sampling strategy is needed for a statistical justification



Statistical justification/rationale: -1, Clause 4.3



# Test Method Validation



ASTM test methods must be validated in the laboratory conducting the test; publication of a method by a standards body does not make it validated in any laboratory (-1, Clause 4.4.3 Note).




## **Design and Development Documentation (DDD)**

Shall have procedures for packaging system design and development (-1, Clause 6.2.1)

- ✓ Most companies have gate checks for devices included in the DDD
- ✓ Need to include the packaging work or have a separate DDD for packaging

# Equipment EQ: IQ and OQ (-2; Clause 5.2) or EIOQ





## Production Qualification (PQ)

Must be a minimum of three lots (-2; Clause 5.4.4)

Best practices include:

- ✓ Analyze the test lots separately to assure they are statistically equivalent\*
- ✓ Consecutive lots used
- ✓ Production stoppages, material lot changes, and similar that may occur should occur during the qualification to simulate 'normal' production

\* Remember there can be 'no practical difference' when something is 'not statistically equivalent', this must be explained in the protocol before testing or a deviation or a protocol failure is required.

# Packaging Stability Testing



Aging the packaging system is independent of the physical configuration or contents, as long as:

- ✓ The processing is the same, and
- ✓ The contents do not affect the materials
- ✓ -1, Clause 8.1 Note 2



ASTM F1980 *Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices*

- ✓ Uses a modified Arrhenius equation:
  - Assumes the chemical reaction rate in a material is a logarithmic change for each 10 degree increase
    - $Q_{10} = 2$  is the usual assumption
    - $Q_{10} \neq 2$  for most PETG (many thermal formed trays)
  - Humidity is not part of the Arrhenius aging considerations



## Relative Humidity Note



**Relative Humidity** is the number of water molecules in the air




The number of molecules in the air is effected by **Temperature**



**Temperature and humidity** are inversely proportional (with a given quantity of moisture)

$$\text{Relative Humidity} = \frac{\text{actual vapor density}}{\text{saturation vapor density}} \times 100\%$$



# Aging verses Performance Testing

Two separate entities per the FDA, ISO, and chemistry books



**Aging tests** a material's stability over time



**Performance testing** evaluates the interaction between the packaging system and the products in response to the stresses imposed by the manufacturing (and sterilization) processes and the handling, storage, and shipping environment



# Performance Testing - ASTM D4169

Test Plan	Description
Handling	6 impacts, 24 inch
Vehicle Stacking (Compression)	Apply & release calculated top load
Loose Load Vibration	Repetitive shock 1 hour
High Altitude	14,000 ft 1 hour
Random Vibration	Three levels for trucks 3 hours
Concentrated Impact	1 impact 36 inches
Handling	5 impacts, 24 inch 6th at 48"



# Performance Test Standards

## ASTM and ISTA Test Standards

- **ASTM D4169:** *Standard Practice for Performance Testing of Shipping Containers and Systems*
- **ASTM D7386:** *Standard Practice Performance Testing of Packages for Single Parcel Delivery Systems*
- **ISTA 3A or Higher**
- **ISTA 2A** Package Conditioning for Testing
- **ASTM D4332:** *Standard Practice for Conditioning Containers, Packages, or Packaging Components for Testing*
- **ASTM F2825:** *Standard Practice for Climatic Stressing of Packaging Systems for Single Parcel Delivery*
- **Develop performance standards based on company distribution system** → the best option but hard for many companies



## Performance Defect Example



- ✓ Performance defect (package design issue), not an aging defect
- ✓ Do not confuse the two types of defects



# Product Acceptability after Performance/ Distribution/Transit/Ship Testing

“Shall” statement to test product (-1, Clause 8.2.1 Note 2)

Package Engineering or Product Development must test the product after transit tests

Logistically, usually easiest to keep product testing and package testing separate

- ✓ However, must assure both departments use the same transit tests
- ✓ Many companies test packaging and product separately






# Understand the Distribution System Using



# Distribution Mapping -- General



# Distribution Mapping: Detailed Multiple Shipping Count Example

## *Domestic System and Domestic Repetition*

<b>Round trip</b>	<b>Handling</b>	<b>Truck Transit</b>	<b>Plane Transit</b>	<b>Compression</b>
1	23	6	1	3
2	47	13	3	7
3	71	20	5	11
4	95	27	7	15
5	119	34	9	19
6	143	41	11	23

## *International with Subassembly and International Repetition*

<b>Round trip</b>	<b>Handling</b>	<b>Truck Transit</b>	<b>Plane Transit</b>	<b>Compression</b>
1	37	10	3	7
2	77	21	7	15
3	124	32	11	23
4	171	43	15	31
5	218	54	19	39
6	265	65	23	47



# Update



**2019 ISO 11607-1/-2 Standards:  
New Changes in the revised documents**



# Opinions on the ISO 11607-1/-2 Revisions



Most revisions for clarifications

*My opinion:*

The revisions have some good changes by removing a few unnecessary complications. The wording more clearly defines some previously implied intents and adds human factors (called “usability requirements”).

Removing “critical” process parameters in -2 gives more focus on the whole production process.



## Major Changes Summary from ISO 11607-1 (2014)

- Eliminates the sample testing requirements of  $23^{\circ}\text{C} \pm 1^{\circ}\text{C}$  and  $50\% \text{RH} \pm 2\%$
- The sterile barrier system *shall* allow the product to be presented in an aseptic manner (*with notation to see the “usability” clause*).
- New clause on **Usability Evaluation added (human factors)**
- Clause added for Reusable Sterile Barrier Systems and potential degradation limiting shelf life labeling requirements
- More explanation on “hazards” and “performance testing” with worst-case packaging system/SBS, and validated packaging system changes
- Real-time testing and accelerated testing shall start within three months of each other
- Sustainability Annex D added
- Labeling requirements for sterile barrier system to be inspected for integrity before use (Annex E)**



## Major Changes Summary from ISO 11607-2 (2014)

- New definitions for process - variables, parameter, and specification
- Added Risk Management section
- Harmonize definitions with ISO 11139
- “Critical” process parameters is discontinued - to include all elements required to manufacture a product that consistently meets specifications
- Note added to “revalidation” allowing targeted process validations based on design validation work
- Periodic review removed with minor process changes to be documented for potential to require the process validation status to be reviewed



# Information to Understand



## Human factors

- ✓ FDA and AAMI have guidance documents
  - Both are very device oriented so hard to determine what is best
  - Pharmaceuticals are conducting human factor testing on child resistant closures and blister tablets
  - Michigan State University, Dr. Bix and her graduate students, are doing studies
  - Document the company studies





# Human Factors and Design






# ISO 11607-1: 2019

Complying with the new ISO 11607-1 requires:

- ✓ Sterile barrier inspection before use required and a symbol to show what is the sterile barrier layer
- ✓ Proposed symbols are not finalized and require validation

*Note:* UDI for Europe and the USA to comply with trace-ability requirements but is not discussed in ISO 11607-1/-2 standards or in this presentation

## Proposed New Symbol Examples





## **New Challenges: New Concerns in Discussion**



## Third Party Distributors

- ✓ Product often packed into plastic boxes, placed on wire racks, and shipped by truck to a hospital
- ✓ Some are repacking, relabeling, and bundling products without performing validations
- ✓ Handling unclear





## Hospital Handling



ANY  
QUESTIONS?



# AdeptPackaging

PACKAGING ENGINEERS & CONSULTANTS

*Engineering Packaging Excellence*

**Jan Gates**

Adept Packaging

VP, Client Solutions - West Coast

E-mail: [jan.gates@adeptpackaging.com](mailto:jan.gates@adeptpackaging.com)

Based in Temecula, CA

Adept Group LLC

One East Broad Street, Bethlehem PA 18018

+1.484.373.2504 | [info@adeptpkg.com](mailto:info@adeptpkg.com)

[www.adeptpkg.com](http://www.adeptpkg.com)